Target name

P97266: Mu-type opioid receptor


  Protein function

Receptor for endogenous opioids such as beta-endorphin and endomorphin. Agonist binding to the receptor induces coupling to an inactive GDP-bound heterotrimeric G-protein complex and subsequent exchange of GDP for GTP in the G-protein alpha subunit leading to dissociation of the G-protein complex with the free GTP-bound G-protein alpha and the G-protein beta-gamma dimer activating downstream cellular effectors. The agonist- and cell type-specific activity is predominantly coupled to pertussis toxin-sensitive G(i) and G(o) G alpha proteins, GNAI1, GNAI2, GNAI3 and GNAO1, and to a lesser extend to pertussis toxin-insensitive G alpha proteins GNAZ and GNA15. They mediate an array of downstream cellular responses, including inhibition of adenylate cyclase activity and both N-type and L-type calcium channels, activation of inward rectifying potassium channels, mitogen-activated protein kinase (MAPK), phospholipase C (PLC), phosphoinositide/protein kinase (PKC), phosphoinositide 3-kinase (PI3K) and regulation of NF-kappa-B. Also couples to adenylate cyclase stimulatory G alpha proteins. The selective temporal coupling to G-proteins and subsequent signaling can be regulated by RGSZ proteins, such as RGS9, RGS17 and RGS4. Phosphorylation by members of the GPRK subfamily of Ser/Thr protein kinases and association with beta-arrestins is involved in short-term receptor desensitization. Beta-arrestins associate with the GPRK-phosphorylated receptor and uncouple it from the G-protein thus terminating signal transduction. The phosphorylated receptor is internalized through endocytosis via clathrin-coated pits which involves beta-arrestins. The activation of the ERK pathway occurs either in a G-protein-dependent or a beta-arrestin-dependent manner and is regulated by agonist-specific receptor phosphorylation. Acts as a class A G-protein coupled receptor (GPCR) which dissociates from beta-arrestin at or near the plasma membrane and undergoes rapid recycling. Receptor down-regulation pathways are varying with the agonist and occur dependent or independent of G-protein coupling. Endogenous ligands induce rapid desensitization, endocytosis and recycling. Heterooligomerization with other GPCRs can modulate agonist binding, signaling and trafficking properties. Involved in neurogenesis (By similarity).

  Database links

Uniprot primary ID P97266
GRCP SARfari Variant Name cavOPRM1_1580
PDB ID
DrugBank ID
BioGrid ID
GuidetoPHARMACOLOGY ID
PharmGKB ID
KEGG ID
Entrez Gene (Gene ID)
BindingDB P97266

  Model Performance Metrics

Fingerprint type Sensitivity Specificity Accuracy F1-score AUC Matthews_corrcoef Download model
FP2 fingerprints 0.91 0.68 0.79 0.82 0.83 0.61 Download
FP4 fingerprints 0.920 0.690 0.800 0.820 0.810 0.630 Download
MACCS fingerprints 0.870 0.660 0.760 0.790 0.790 0.540 Download
Daylight fingerprints 0.870 0.710 0.790 0.810 0.800 0.590 Download
ECFP2 fingerprints 0.910 0.710 0.810 0.830 0.850 0.640 Download
ECFP4 fingerprints 0.930 0.730 0.830 0.840 0.870 0.670 Download
ECFP6 fingerprints 0.870 0.740 0.810 0.820 0.870 0.620 Download

  Download datasets

Positive dataset Negative dataset


Copyright @ 2012-2015 Computational Biology & Drug Design Group,
School of Pharmaceutical Sciences, Central South University. All rights reserved.

The recommended browsers: Safari, Firefox, Chrome, IE(Ver.>8).
 E-mail: biomed@csu.edu.cn